載入中
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
最新資料
HK$2.65
+HK$0.015 · +0.57%
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
日內區間
目前HK$2.65
52週區間
目前HK$2.65
歷史價格可能經過調整並有所延遲。
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
日內區間
目前HK$2.65
52週區間
目前HK$2.65
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（CNY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3.56億 CNY | 4.46億 CNY | 6.35億 CNY | 5.67億 CNY | 6026萬 CNY |
| 銷貨成本 | 5712萬 CNY | 7390.9萬 CNY | 1.11億 CNY | 4221.5萬 CNY | 427.7萬 CNY |
| 毛利 | 2.99億 CNY | 3.72億 CNY | 5.24億 CNY | 5.25億 CNY | 5598.3萬 CNY |
| 研究與開發 | 1.56億 CNY | 1.81億 CNY | 4.25億 CNY | 3.51億 CNY | 3.71億 CNY |
| 銷售、一般及管理費用 | 2.56億 CNY | 3.14億 CNY | 5.96億 CNY | 5億 CNY | 1.94億 CNY |
| 營業費用 | 4.12億 CNY | 4.95億 CNY | 10.21億 CNY | 8.47億 CNY | 5.59億 CNY |
| 利息收入 | 2032.89萬 CNY | 1092.3萬 CNY | 653.1萬 CNY | 721萬 CNY | 550.2萬 CNY |
| 利息支出 | 509.37萬 CNY | 950.3萬 CNY | 777.2萬 CNY | 311.3萬 CNY | 152.8萬 CNY |
| 折舊和攤銷 | 1516.2萬 CNY | 2525.1萬 CNY | 2546.1萬 CNY | 2160萬 CNY | 1259.1萬 CNY |
| 營業利益 | −1.13億 CNY | −1.23億 CNY | −4.97億 CNY | −3.86億 CNY | −5.16億 CNY |
| 淨利 | −1.78億 CNY | −1.83億 CNY | −5.25億 CNY | −10.24億 CNY | −14.34億 CNY |
公司資料更新於 2026年10月17日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
